{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:38:00Z","timestamp":1792611480464,"version":"4.5.0"},"reference-count":187,"publisher":"Harborside Press, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). For patients with mCSPC, disease characteristics, such as whether metastases arose synchronously or metachronously and the degree of metastatic burden, impact therapy decisions, including how much treatment intensification is appropriate and when prostate-directed and\/or metastasis-directed therapy should be considered. In the mCRPC setting, androgen deprivation therapy is continued with the sequential or concurrent addition of certain androgen receptor pathway inhibitors, chemotherapies, immunotherapies, radiopharmaceuticals, and\/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, biomarkers, the extent and location of metastases, symptoms, and potential side effects.<\/jats:p>","DOI":"10.6004\/jnccn.2025.0052","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:56:40Z","timestamp":1762783000000},"page":"469-493","source":"Crossref","is-referenced-by-count":138,"title":["Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"23","author":[{"given":"Daniel E.","family":"Spratt","sequence":"first","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Adra","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilawal","family":"Ahmed","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"An","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Bitting","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chapin","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve Y.","family":"Cho","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Victor","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Desai","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"City of Hope National Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Eastham","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Farrington","sequence":"additional","affiliation":[{"name":"Prostate Health Education Network (PHEN)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Ippolito","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeffrey","family":"Karnes","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Kishan","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Kuettel","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Lang","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at The University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Lotan","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McDonald","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Morgan","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Pessoa","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Rais-Bahrami","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack","family":"Roach","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Robin","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"University of California San Francisco Patient Services Committee Chair"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen R.","family":"Scarpato","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Shabsigh","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Szmulewitz","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Teply","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tward","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Valicenti","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"VanderWeele","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Karen","family":"Wong","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kovach","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Freedman-Cass","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B2","series-title":"Ann Intern Med","first-page":"120","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer VA","year":"2012","unstructured":"Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120\u2013134."},{"key":"B3","series-title":"J Urol","first-page":"1587","article-title":"Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States","volume":"194","author":"Barocas DA","year":"2015","unstructured":"Barocas DA, Mallin K, Graves AJ,  Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol 2015;194:1587\u20131593."},{"key":"B4","series-title":"J Clin Oncol","first-page":"2416","article-title":"National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening","volume":"33","author":"Drazer MW","year":"2015","unstructured":"Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416\u20132423."},{"key":"B5","series-title":"JAMA Oncol","first-page":"955","article-title":"Recent trends in PSA testing and prostate cancer incidence: a look at context","volume":"2","author":"Etzioni R","year":"2016","unstructured":"Etzioni R, Gulati R. Recent trends in PSA testing and prostate cancer incidence: a look at context. JAMA Oncol 2016;2:955\u2013956."},{"key":"B6","series-title":"JAMA Intern Med","first-page":"1040","article-title":"Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States","volume":"177","author":"Fedewa SA","year":"2017","unstructured":"Fedewa SA, Ward EM, Brawley O, Jemal A. Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med 2017;177:1040\u20131042."},{"key":"B7","series-title":"J Urol","first-page":"676","article-title":"Trends in prostate cancer incidence rates and prevalence of prostate-specific antigen screening by socioeconomic status and regions in the US, 2004\u20132013","volume":"199","author":"Houston KA","year":"2018","unstructured":"Houston KA, King J, Li J, Jemal A. Trends in prostate cancer incidence rates and prevalence of prostate-specific antigen screening by socioeconomic status and regions in the US, 2004\u20132013. J Urol 2018;199:676\u2013682."},{"key":"B8","series-title":"Cancer","first-page":"2733","article-title":"PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening","volume":"124","author":"Kearns JT","year":"2018","unstructured":"Kearns JT, Holt SK, Wright JL,  PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Cancer 2018;124:2733\u20132739."},{"key":"B9","series-title":"JAMA","first-page":"2054","article-title":"Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations","volume":"314","author":"Jemal A","year":"2015","unstructured":"Jemal A, Fedewa SA, Ma J,  Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054\u20132061."},{"key":"B10","series-title":"JAMA","first-page":"2077","article-title":"Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations","volume":"314","author":"Sammon JD","year":"2015","unstructured":"Sammon JD, Abdollah F, Choueiri TK,  Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations. JAMA 2015;314:2077\u20132079."},{"key":"B11","series-title":"CA Cancer J Clin","first-page":"111","article-title":"Cancer statistics for African American and Black people, 2025","volume":"75","author":"Saka AH","year":"2025","unstructured":"Saka AH, Giaquinto AN, McCullough LE,  Cancer statistics for African American and Black people, 2025. CA Cancer J Clin 2025;75:111\u2013140."},{"key":"B12","series-title":"JAMA Oncol","first-page":"975","article-title":"Association of Black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess RT","year":"2019","unstructured":"Dess RT, Hartman HE, Mahal BA,  Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 2019;5:975\u2013983."},{"key":"B13","series-title":"N Engl J Med","first-page":"352","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi K","year":"2017","unstructured":"Fizazi K, Tran N, Fein L,  Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352\u2013360."},{"key":"B14","series-title":"Lancet Oncol","first-page":"686","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi K","year":"2019","unstructured":"Fizazi K, Tran N, Fein L,  Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:686\u2013700."},{"key":"B15","series-title":"Lancet Oncol","first-page":"194","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi KN","year":"2018","unstructured":"Chi KN, Protheroe A, Rodriguez-Antolin A,  Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol 2018;19:194\u2013206."},{"key":"B16","series-title":"N Engl J Med","first-page":"338","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James ND","year":"2017","unstructured":"James ND, de Bono JS, Spears MR,  Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338\u2013351."},{"key":"B17","series-title":"J Clin Oncol","first-page":"1389","article-title":"Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer","volume":"36","author":"Szmulewitz RZ","year":"2018","unstructured":"Szmulewitz RZ, Peer CJ, Ibraheem A,  Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 2018;36:1389\u20131395."},{"key":"B18","series-title":"N Engl J Med","first-page":"13","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi KN","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A,  Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381:13\u201324."},{"key":"B19","series-title":"Lancet Oncol","first-page":"1518","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal N","year":"2019","unstructured":"Agarwal N, McQuarrie K, Bjartell A,  Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol 2019;20:1518\u20131530."},{"key":"B20","series-title":"J Clin Oncol","first-page":"2294","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi KN","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A,  Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39:2294\u20132303."},{"key":"B21","series-title":"N Engl J Med","first-page":"121","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis ID","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR,  Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121\u2013131."},{"key":"B22","series-title":"Lancet Oncol","first-page":"323","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney CJ","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR,  Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24:323\u2013334."},{"key":"B23","series-title":"J Clin Oncol","first-page":"2974","article-title":"ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong AJ","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP,  ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37:2974\u20132986."},{"key":"B24","series-title":"J Clin Oncol","first-page":"1616","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong AJ","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T,  Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2022;40:1616\u20131622."},{"key":"B25","series-title":"J Clin Oncol","first-page":"4271","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad F","year":"2024","unstructured":"Saad F, Vjaters E, Shore N,  Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol 2024;42:4271\u20134281."},{"key":"B26","series-title":"Lancet","first-page":"1163","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James ND","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW,  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163\u20131177."},{"key":"B27","series-title":"N Engl J Med","first-page":"737","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M,  Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737\u2013746."},{"key":"B28","series-title":"J Clin Oncol","first-page":"1080","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos CE","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA,  Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080\u20131087."},{"key":"B29","series-title":"Lancet Oncol","first-page":"149","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis G","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F,  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149\u2013158."},{"key":"B30","series-title":"Eur Urol","first-page":"256","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis G","year":"2016","unstructured":"Gravis G, Boher JM, Joly F,  Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70:256\u2013262."},{"key":"B31","series-title":"Lancet","first-page":"1695","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi K","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J,  Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet 2022;399:1695\u20131707."},{"key":"B32","series-title":"N Engl J Med","first-page":"1132","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith MR","year":"2022","unstructured":"Smith MR, Hussain M, Saad F,  Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386:1132\u20131142."},{"key":"B33","series-title":"Lancet Oncol","first-page":"783","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale CL","year":"2023","unstructured":"Vale CL, Fisher DJ, Godolphin PJ,  Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol 2023;24:783\u2013797."},{"key":"B34","series-title":"J Clin Oncol","first-page":"3595","article-title":"Darolutamide plus androgen- deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain M","year":"2023","unstructured":"Hussain M, Tombal B, Saad F,  Darolutamide plus androgen- deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol 2023;41:3595\u20133607."},{"key":"B35","series-title":"Lancet","first-page":"2353","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker CC","year":"2018","unstructured":"Parker CC, James ND, Brawley CD,  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353\u20132366."},{"key":"B36","series-title":"PLoS Med","first-page":"e1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker CC","year":"2022","unstructured":"Parker CC, James ND, Brawley CD,  Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med 2022;19:e1003998."},{"key":"B37","series-title":"Lancet","first-page":"2065","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"404","author":"Bossi A","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X,  Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet 2024;404:2065\u20132076."},{"key":"B38","series-title":"JAMA Oncol","first-page":"555","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial","volume":"7","author":"Ali A","year":"2021","unstructured":"Ali A, Hoyle A, Haran AM,  Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2021;7:555\u2013563."},{"key":"B39","series-title":"J Clin Oncol","first-page":"3377","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek MP","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P,  Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 2022;40:3377\u20133382."},{"key":"B40","series-title":"J Clin Oncol","first-page":"5561","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)","volume":"41","author":"Francolini G","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B,  Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol 2023;41:5561\u20135568."},{"key":"B41","series-title":"Lancet Oncol","first-page":"300","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso G","year":"2025","unstructured":"Marvaso G, Corrao G, Zaffaroni M,  ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol 2025;26:300\u2013311."},{"key":"B42","series-title":"JAMA Oncol","first-page":"825","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang C","year":"2023","unstructured":"Tang C, Sherry AD, Haymaker C,  Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol 2023;9:825\u2013834."},{"key":"B43","series-title":"J Clin Oncol","first-page":"446","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost P","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K,  Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446\u2013453."},{"key":"B44","series-title":"JAMA Oncol","first-page":"650","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips R","year":"2020","unstructured":"Phillips R, Shi WY, Deek M,  Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 2020;6:650\u2013659."},{"key":"B45","series-title":"Eur Urol","article-title":"Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial","author":"Sherry AD","unstructured":"Sherry AD, Siddiqui BA, Haymaker C,  Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial. Eur Urol. Published online July 31, 2025. doi:10.1016\/j.eururo.2025.07.006"},{"key":"B46","series-title":"J Clin Oncol","first-page":"2830","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma DA","year":"2020","unstructured":"Palma DA, Olson R, Harrow S,  Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 2020;38:2830\u20132838."},{"key":"B47","series-title":"J Clin Oncol","first-page":"1148","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher HI","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I,  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148\u20131159."},{"key":"B48","series-title":"J Clin Oncol","first-page":"2918","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith MR","year":"2005","unstructured":"Smith MR, Kabbinavar F, Saad F,  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918\u20132925."},{"key":"B49","series-title":"JCO Precis Oncol","first-page":"PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"2017","author":"Abida W","year":"2017","unstructured":"Abida W, Armenia J, Gopalan A,  Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017;2017:PO.17.00029."},{"key":"B50","series-title":"Clin Cancer Res","first-page":"4854","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan CJ","year":"2011","unstructured":"Ryan CJ, Shah S, Efstathiou E,  Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17:4854\u20134861."},{"key":"B51","series-title":"J Clin Oncol","first-page":"1402","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher HI","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM,  Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402\u20131418."},{"key":"B52","series-title":"Am J Pathol","first-page":"217","article-title":"Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance","volume":"164","author":"Holzbeierlein J","year":"2004","unstructured":"Holzbeierlein J, Lal P, LaTulippe E,  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217\u2013227."},{"key":"B53","series-title":"Clin Cancer Res","first-page":"440","article-title":"The androgen axis in recurrent prostate cancer","volume":"10","author":"Mohler JL","year":"2004","unstructured":"Mohler JL, Gregory CW, Ford OH,  The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440\u2013448."},{"key":"B54","series-title":"N Engl J Med","first-page":"1995","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono JS","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A,  Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995\u20132005."},{"key":"B55","series-title":"Lancet Oncol","first-page":"983","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi K","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A,  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983\u2013992."},{"key":"B56","series-title":"Lancet Oncol","first-page":"1210","article-title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial","volume":"13","author":"Logothetis CJ","year":"2012","unstructured":"Logothetis CJ, Basch E, Molina A,  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012;13:1210\u20131217."},{"key":"B57","series-title":"N Engl J Med","first-page":"138","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan CJ","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS,  Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138\u2013148."},{"key":"B58","series-title":"Lancet Oncol","first-page":"152","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan CJ","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K,  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152\u2013160."},{"key":"B59","series-title":"Cancer Chemother Pharmacol","first-page":"479","article-title":"Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate","volume":"80","author":"Hussaini A","year":"2017","unstructured":"Hussaini A, Olszanski AJ, Stein CA,  Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. Cancer Chemother Pharmacol 2017;80:479\u2013486."},{"key":"B60","series-title":"Clin Pharmacokinet","first-page":"803","article-title":"Comparison of a novel formulation of abiraterone acetate vs. the originator formulation in healthy male subjects: two randomized, open-label, crossover studies","volume":"56","author":"Goldwater R","year":"2017","unstructured":"Goldwater R, Hussaini A, Bosch B, Nemeth P. Comparison of a novel formulation of abiraterone acetate vs. the originator formulation in healthy male subjects: two randomized, open-label, crossover studies. Clin Pharmacokinet 2017;56:803\u2013813."},{"key":"B61","series-title":"Urol Oncol","first-page":"81.e9","article-title":"Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: the STAAR study","volume":"36","author":"Stein CA","year":"2018","unstructured":"Stein CA, Levin R, Given R,  Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: the STAAR study. Urol Oncol 2018;36:81.e9\u201316."},{"key":"B62","series-title":"Br J Cancer","first-page":"1052","article-title":"Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)","volume":"119","author":"Romero-Laorden N","year":"2018","unstructured":"Romero-Laorden N, Lozano R, Jayaram A,  Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer 2018;119:1052\u20131059."},{"key":"B63","series-title":"BJU Int","first-page":"300","article-title":"Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer","volume":"123","author":"Fenioux C","year":"2019","unstructured":"Fenioux C, Louvet C, Charton E,  Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU Int 2019;123:300\u2013306."},{"key":"B64","series-title":"N Engl J Med","first-page":"1187","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher HI","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F,  Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187\u20131197."},{"key":"B65","series-title":"Lancet Oncol","first-page":"1147","article-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial","volume":"15","author":"Fizazi K","year":"2014","unstructured":"Fizazi K, Scher HI, Miller K,  Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014;15:1147\u20131156."},{"key":"B66","article-title":"Drugs@FDA: FDA-Approved Drugs","unstructured":"U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. Accessed August 15, 2025. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"B67","series-title":"N Engl J Med","first-page":"424","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer TM","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE,  Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424\u2013433."},{"key":"B68","series-title":"Eur Urol","first-page":"151","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer TM","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D,  Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 2017;71:151\u2013154."},{"key":"B69","series-title":"N Engl J Med","first-page":"2465","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain M","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F,  Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378:2465\u20132474."},{"key":"B70","series-title":"N Engl J Med","first-page":"2197","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg CN","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F,  Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2020;382:2197\u20132206."},{"key":"B71","series-title":"Lancet Oncol","first-page":"556","article-title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","volume":"20","author":"Tombal B","year":"2019","unstructured":"Tombal B, Saad F, Penson D,  Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:556\u2013569."},{"key":"B72","series-title":"N Engl J Med","first-page":"1408","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith MR","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S,  Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378:1408\u20131418."},{"key":"B73","series-title":"Lancet Oncol","first-page":"1404","article-title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Saad F","year":"2018","unstructured":"Saad F, Cella D, Basch E,  Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:1404\u20131416."},{"key":"B74","series-title":"Eur Urol","first-page":"150","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith MR","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S,  Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79:150\u2013158."},{"key":"B75","series-title":"N Engl J Med","first-page":"1235","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi K","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL,  Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380:1235\u20131246."},{"key":"B76","series-title":"N Engl J Med","first-page":"1040","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi K","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL,  Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383:1040\u20131049."},{"key":"B77","series-title":"J Clin Oncol","first-page":"1025","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","volume":"22","author":"Small EJ","year":"2004","unstructured":"Small EJ, Halabi S, Dawson NA,  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025\u20131033."},{"key":"B78","series-title":"J Urol","first-page":"908","article-title":"Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy","volume":"150","author":"Dupont A","year":"1993","unstructured":"Dupont A, Gomez JL, Cusan L,  Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150:908\u2013913."},{"key":"B79","series-title":"Cancer","first-page":"2393","article-title":"Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)","volume":"112","author":"Sartor AO","year":"2008","unstructured":"Sartor AO, Tangen CM, Hussain MH,  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112:2393\u20132400."},{"key":"B80","series-title":"J Clin Oncol","first-page":"1371","article-title":"TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer","volume":"39","author":"Denmeade SR","year":"2021","unstructured":"Denmeade SR, Wang H, Agarwal N,  TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer. J Clin Oncol 2021;39:1371\u20131382."},{"key":"B81","series-title":"N Engl J Med","first-page":"1513","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak DP","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH,  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513\u20131520."},{"key":"B82","series-title":"N Engl J Med","first-page":"1502","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock IF","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR,  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502\u20131512."},{"key":"B83","series-title":"J Clin Oncol","first-page":"242","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold DR","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F,  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242\u2013245."},{"key":"B84","series-title":"Lancet Oncol","first-page":"117","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen PL","year":"2013","unstructured":"Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T,  2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013;14:117\u2013124."},{"key":"B85","series-title":"JAMA Oncol","first-page":"68","article-title":"Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the mainsail study","volume":"3","author":"de Morree ES","year":"2017","unstructured":"de Morree ES, Vogelzang NJ, Petrylak DP,  Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the mainsail study. JAMA Oncol 2017;3:68\u201375."},{"key":"B86","series-title":"Eur Urol","first-page":"696","article-title":"Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial","volume":"73","author":"Lavaud P","year":"2018","unstructured":"Lavaud P, Gravis G, Foulon S,  Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial. Eur Urol 2018;73:696\u2013703."},{"key":"B87","series-title":"Lancet","first-page":"1147","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono JS","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M,  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147\u20131154."},{"key":"B88","series-title":"Ann Oncol","first-page":"2402","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl A","year":"2013","unstructured":"Bahl A, Oudard S, Tombal B,  Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013;24:2402\u20132408."},{"key":"B89","series-title":"Eur J Cancer","first-page":"93","article-title":"Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial","volume":"56","author":"Meisel A","year":"2016","unstructured":"Meisel A, von Felten S, Vogt DR,  Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial. Eur J Cancer 2016;56:93\u2013100."},{"key":"B90","series-title":"N Engl J Med","first-page":"2506","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit R","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN,  Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381:2506\u20132518."},{"key":"B91","series-title":"Lancet Oncol","first-page":"1513","article-title":"Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study","volume":"21","author":"Fizazi K","year":"2020","unstructured":"Fizazi K, Kramer G, Eymard JC,  Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncol 2020;21:1513\u20131525."},{"key":"B92","series-title":"J Clin Oncol","first-page":"3198","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger M","year":"2017","unstructured":"Eisenberger M, Hardy-Bessard AC, Kim CS,  Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 2017;35:3198\u20133206."},{"key":"B93","series-title":"J Clin Oncol","first-page":"3189","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA","volume":"35","author":"Oudard S","year":"2017","unstructured":"Oudard S, Fizazi K, Sengelov L,  Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 2017;35:3189\u20133197."},{"key":"B94","series-title":"JAMA Oncol","first-page":"1629","article-title":"Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial","volume":"9","author":"Oudard S","year":"2023","unstructured":"Oudard S, Ratta R, Voog E,  Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial. JAMA Oncol 2023;9:1629\u20131638."},{"key":"B95","series-title":"Cancer Chemother Pharmacol","first-page":"339","article-title":"Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study","volume":"79","author":"Sarantopoulos J","year":"2017","unstructured":"Sarantopoulos J, Mita AC, He A,  Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer Chemother Pharmacol 2017;79:339\u2013351."},{"key":"B96","series-title":"Lancet Oncol","first-page":"1432","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial","volume":"20","author":"Corn PG","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A,  Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial. Lancet Oncol 2019;20:1432\u20131443."},{"key":"B97","series-title":"N Engl J Med","first-page":"411","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff PW","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND,  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411\u2013422."},{"key":"B98","series-title":"Cancer","first-page":"4172","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano CS","year":"2019","unstructured":"Higano CS, Armstrong AJ, Sartor AO,  Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer 2019;125:4172\u20134180."},{"key":"B99","series-title":"Oncotarget","first-page":"52810","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff JN","year":"2016","unstructured":"Graff JN, Alumkal JJ, Drake CG,  Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016;7:52810\u201352817."},{"key":"B100","series-title":"Science","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","unstructured":"Le DT, Durham JN, Smith KN,  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409\u2013413."},{"key":"B101","series-title":"Ann Oncol","first-page":"1807","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","volume":"29","author":"Hansen AR","year":"2018","unstructured":"Hansen AR, Massard C, Ott PA,  Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 2018;29:1807\u20131813."},{"key":"B102","series-title":"JAMA Oncol","first-page":"471","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida W","year":"2019","unstructured":"Abida W, Cheng ML, Armenia J,  Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 2019;5:471\u2013478."},{"key":"B103","series-title":"Cancer Med","first-page":"4644","article-title":"Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer","volume":"8","author":"Tucker MD","year":"2019","unstructured":"Tucker MD, Zhu J, Marin D,  Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Med 2019;8:4644\u20134655."},{"key":"B104","series-title":"J Clin Oncol","first-page":"1","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA,  Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1\u201310."},{"key":"B105","series-title":"J Clin Oncol","first-page":"395","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis ES","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M,  Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020;38:395\u2013405."},{"key":"B106","series-title":"Cell","first-page":"1215","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson D","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM,  Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215\u20131228."},{"key":"B107","series-title":"Clin Cancer Res","first-page":"3894","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis AT","year":"2024","unstructured":"Lenis AT, Ravichandran V, Brown S,  Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clin Cancer Res 2024;30:3894\u20133903."},{"key":"B108","series-title":"Lancet Oncol","first-page":"1353","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J,  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353\u20131365."},{"key":"B109","series-title":"J Clin Oncol","first-page":"1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone- resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock IF","year":"1996","unstructured":"Tannock IF, Osoba D, Stockler MR,  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone- resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756\u20131764."},{"key":"B110","series-title":"J Clin Oncol","first-page":"2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff PW","year":"1999","unstructured":"Kantoff PW, Halabi S, Conaway M,  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506\u20132513."},{"key":"B111","series-title":"J Clin Oncol","first-page":"244","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman B","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK,  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 2015;33:244\u2013250."},{"key":"B112","series-title":"N Engl J Med","first-page":"1697","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo J","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S,  DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373:1697\u20131708."},{"key":"B113","series-title":"Lancet Oncol","first-page":"975","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke N","year":"2018","unstructured":"Clarke N, Wiechno P, Alekseev B,  Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2018;19:975\u2013986."},{"key":"B114","series-title":"Nature","first-page":"917","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer H","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ,  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917\u2013921."},{"key":"B115","series-title":"Hered Cancer Clin Pract","first-page":"5","article-title":"Drug therapy for hereditary cancers","volume":"9","author":"Imyanitov EN","year":"2011","unstructured":"Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5."},{"key":"B116","series-title":"Eur Urol","first-page":"992","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng HH","year":"2016","unstructured":"Cheng HH, Pritchard CC, Boyd T,  Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 2016;69:992\u2013995."},{"key":"B117","series-title":"Cancer","first-page":"3532","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","volume":"123","author":"Pomerantz MM","year":"2017","unstructured":"Pomerantz MM, Spisak S, Jia L,  The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 2017;123:3532\u20133539."},{"key":"B118","series-title":"JCO Precis Oncol","first-page":"355","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota JM","year":"2020","unstructured":"Mota JM, Barnett E, Nauseef JT,  Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations. JCO Precis Oncol 2020;4:355\u2013366."},{"key":"B119","series-title":"JAMA Netw Open","first-page":"e2021692","article-title":"Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations","volume":"3","author":"Schmid S","year":"2020","unstructured":"Schmid S, Omlin A, Higano C,  Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations. JAMA Netw Open 2020;3:e2021692."},{"key":"B120","series-title":"Ann Oncol","first-page":"975","article-title":"Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review","volume":"27","author":"Hager S","year":"2016","unstructured":"Hager S, Ackermann CJ, Joerger M,  Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 2016;27:975\u2013984."},{"key":"B121","series-title":"J Clin Oncol","first-page":"490","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro E","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A,  PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2019;37:490\u2013503."},{"key":"B122","series-title":"Eur Urol","first-page":"218","article-title":"Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide","volume":"74","author":"Antonarakis ES","year":"2018","unstructured":"Antonarakis ES, Lu C, Luber B,  Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol 2018;74:218\u2013225."},{"key":"B123","series-title":"Eur Urol","first-page":"687","article-title":"Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study","volume":"73","author":"Mateo J","year":"2018","unstructured":"Mateo J, Cheng HH, Beltran H,  Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study. Eur Urol 2018;73:687\u2013693."},{"key":"B124","series-title":"JCO Precis Oncol","first-page":"370","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis ES","year":"2020","unstructured":"Antonarakis ES, Isaacsson Velho P, Fu W,  CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis Oncol 2020;4:370\u2013381."},{"key":"B125","series-title":"JCO Precis Oncol","first-page":"382","article-title":"CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade","volume":"4","author":"Schweizer MT","year":"2020","unstructured":"Schweizer MT, Ha G, Gulati R,  CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade. JCO Precis Oncol 2020;4:382\u2013392."},{"key":"B126","series-title":"Clin Cancer Res","first-page":"3200","article-title":"Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial","volume":"30","author":"Nguyen CB","year":"2024","unstructured":"Nguyen CB, Reimers MA, Perera C,  Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial. Clin Cancer Res 2024;30:3200\u20133210."},{"key":"B127","series-title":"Ann Oncol","first-page":"1126","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe S","year":"2024","unstructured":"van Wilpe S, Kloots ISH, Slootbeek PHJ,  Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Ann Oncol 2024;35:1126\u20131137."},{"key":"B128","series-title":"Lancet Oncol","first-page":"162","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo J","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D,  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21:162\u2013174."},{"key":"B129","series-title":"N Engl J Med","first-page":"2091","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono J","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K,  Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382:2091\u20132102."},{"key":"B130","series-title":"N Engl J Med","first-page":"2345","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain M","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K,  Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020;383: 2345\u20132357."},{"key":"B131","series-title":"J Clin Oncol","first-page":"3763","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida W","year":"2020","unstructured":"Abida W, Patnaik A, Campbell D,  Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020;38:3763\u20133772."},{"key":"B132","series-title":"Eur Urol","first-page":"321","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida W","year":"2023","unstructured":"Abida W, Campbell D, Patnaik A,  Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur Urol 2023;84:321\u2013330."},{"key":"B133","series-title":"N Engl J Med","first-page":"719","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi K","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN,  Rucaparib or physician's choice in metastatic prostate cancer. N Engl J Med 2023;388:719\u2013732."},{"key":"B134","series-title":"Clin Cancer Res","first-page":"2487","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida W","year":"2020","unstructured":"Abida W, Campbell D, Patnaik A,  Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res 2020;26:2487\u20132496."},{"key":"B135","series-title":"Cancer Discov","first-page":"1134","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer MJ","year":"2012","unstructured":"Schiewer MJ, Goodwin JF, Han S,  Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012;2:1134\u20131149."},{"key":"B136","series-title":"Cancer Discov","first-page":"1245","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn WR","year":"2013","unstructured":"Polkinghorn WR, Parker JS, Lee MX,  Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013;3:1245\u20131253."},{"key":"B137","series-title":"Sci Signal","first-page":"eaam7479","article-title":"Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li L","year":"2017","unstructured":"Li L, Karanika S, Yang G,  Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 2017;10:eaam7479."},{"key":"B138","series-title":"NEJM Evid","first-page":"EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke NW","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A,  Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1:EVIDoa2200043."},{"key":"B139","series-title":"Lancet Oncol","first-page":"1094","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad F","year":"2023","unstructured":"Saad F, Clarke NW, Oya M,  Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24:1094\u20131108."},{"key":"B140","series-title":"Lancet Oncol","first-page":"1250","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono JS","year":"2021","unstructured":"de Bono JS, Mehra N, Scagliotti GV,  Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol 2021;22:1250\u20131264."},{"key":"B141","series-title":"Lancet","first-page":"291","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal N","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J,  Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2023;402:291\u2013303."},{"key":"B142","series-title":"Lancet","first-page":"447","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal N","year":"2025","unstructured":"Agarwal N, Azad AA, Carles J,  Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 2025;406:447\u2013460."},{"key":"B143","series-title":"J Clin Oncol","first-page":"3339","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi KN","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR,  Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol 2023;41:3339\u20133351."},{"key":"B144","series-title":"Ann Oncol","first-page":"772","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi KN","year":"2023","unstructured":"Chi KN, Sandhu S, Smith MR,  Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol 2023;34:772\u2013782."},{"key":"B145","series-title":"N Engl J Med","first-page":"1091","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor O","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN,  Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385:1091\u20131103."},{"key":"B146","series-title":"Lancet","first-page":"1227","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris MJ","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K,  177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 2024;404:1227\u20131239."},{"key":"B147","series-title":"N Engl J Med","first-page":"213","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker C","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D,  Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213\u2013223."},{"key":"B148","series-title":"Lancet Oncol","first-page":"1397","article-title":"Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial","volume":"15","author":"Hoskin P","year":"2014","unstructured":"Hoskin P, Sartor O, O\u2019Sullivan JM,  Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397\u20131406."},{"key":"B149","series-title":"Lancet Oncol","first-page":"738","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor O","year":"2014","unstructured":"Sartor O, Coleman R, Nilsson S,  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15:738\u2013746."},{"key":"B150","series-title":"Ann Oncol","first-page":"868","article-title":"Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study","volume":"27","author":"Nilsson S","year":"2016","unstructured":"Nilsson S, Cislo P, Sartor O,  Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 2016;27:868\u2013874."},{"key":"B151","series-title":"Lancet Oncol","first-page":"408","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith M","year":"2019","unstructured":"Smith M, Parker C, Saad F,  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:408\u2013419."},{"key":"B152","series-title":"Ann Oncol","first-page":"1058","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal B","year":"2025","unstructured":"Tombal B, Choudhury A, Saad F,  Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann Oncol 2025;36:1058\u20131067."},{"key":"B153","series-title":"J Clin Oncol","first-page":"Abstract 5002","article-title":"Decreased fracture rate by mandating bone protecting agents in the EORTC 1333\/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: an updated safety analysis","volume":"39","author":"Gillessen S","year":"2021","unstructured":"Gillessen S, Choudhury A, Rodriguez-Vida A,  Decreased fracture rate by mandating bone protecting agents in the EORTC 1333\/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: an updated safety analysis. J Clin Oncol 2021;39(Suppl):Abstract 5002."},{"key":"B154","series-title":"Prostate Cancer Prostatic Dis","article-title":"Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)","author":"Francolini G","unstructured":"Francolini G, Bertini N, Di Cataldo V,  Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719). Prostate Cancer Prostatic Dis. Published online February 19, 2025. doi:10.1038\/s41391-025-00950-3"},{"key":"B155","series-title":"J Clin Oncol","first-page":"Abstract 22","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: a randomized phase II trial (GROUQ-PCS 9)","volume":"43","author":"Niazi T","year":"2025","unstructured":"Niazi T, Saad F, Koul R,  Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: a randomized phase II trial (GROUQ-PCS 9). J Clin Oncol 2025;43(Suppl):Abstract 22."},{"key":"B156","series-title":"J Clin Oncol","first-page":"e386","article-title":"Challenges in recognizing treatment-related neuroendocrine prostate cancer","volume":"30","author":"Beltran H","year":"2012","unstructured":"Beltran H, Tagawa ST, Park K,  Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012;30:e386\u2013389."},{"key":"B157","series-title":"J Clin Oncol","first-page":"2492","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal R","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ,  Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 2018;36:2492\u20132503."},{"key":"B158","series-title":"Cancer","first-page":"888","article-title":"Should extrapulmonary small cell cancer be managed like small cell lung cancer?","volume":"116","author":"Brennan SM","year":"2010","unstructured":"Brennan SM, Gregory DL, Stillie A,  Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer 2010;116:888\u2013895."},{"key":"B159","series-title":"Eur Urol","first-page":"250","article-title":"Low PSA metastatic androgen-independent prostate cancer","volume":"38","author":"Sella A","year":"2000","unstructured":"Sella A, Konichezky M, Flex D,  Low PSA metastatic androgen-independent prostate cancer. Eur Urol 2000;38:250\u2013254."},{"key":"B160","series-title":"Cancer","first-page":"1729","article-title":"Treatment outcomes of small cell carcinoma of the prostate: a single-center study","volume":"110","author":"Spiess PE","year":"2007","unstructured":"Spiess PE, Pettaway CA, Vakar-Lopez F,  Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007;110:1729\u20131737."},{"key":"B161","series-title":"J Natl Cancer Inst","first-page":"1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad F","year":"2002","unstructured":"Saad F, Gleason DM, Murray R,  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458\u20131468."},{"key":"B162","series-title":"J Natl Cancer Inst","first-page":"879","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad F","year":"2004","unstructured":"Saad F, Gleason DM, Murray R,  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879\u2013882."},{"key":"B163","series-title":"JAMA Oncol","first-page":"493","article-title":"Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the trapeze randomized clinical trial","volume":"2","author":"James ND","year":"2016","unstructured":"James ND, Pirrie SJ, Pope AM,  Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the trapeze randomized clinical trial. JAMA Oncol 2016;2:493\u2013499."},{"key":"B164","series-title":"Lancet","first-page":"813","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi K","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M,  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813\u2013822."},{"key":"B165","series-title":"JAMA","first-page":"48","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein AL","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL,  Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 2017;317:48\u201358."},{"key":"B166","series-title":"J Clin Oncol","first-page":"1143","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith MR","year":"2014","unstructured":"Smith MR, Halabi S, Ryan CJ,  Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 2014;32:1143\u20131150."},{"key":"B167","series-title":"Br J Cancer","first-page":"1736","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman RE","year":"2008","unstructured":"Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98:1736\u20131740."},{"key":"B168","series-title":"J Oral Maxillofac Surg","first-page":"1238","article-title":"Avascular necrosis of the jaws: risk factors in metastatic cancer patients","volume":"61","author":"Tarassoff P","year":"2003","unstructured":"Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238\u20131239."},{"key":"B169","series-title":"Lancet","first-page":"39","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith MR","year":"2012","unstructured":"Smith MR, Saad F, Coleman R,  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39\u201346."},{"key":"B170","series-title":"Ann Oncol","first-page":"1802","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan KL","year":"2013","unstructured":"Noonan KL, North S, Bitting RL,  Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24:1802\u20131807."},{"key":"B171","series-title":"Ann Oncol","first-page":"1807","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot Y","year":"2013","unstructured":"Loriot Y, Bianchini D, Ileana E,  Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807\u20131812."},{"key":"B172","series-title":"Eur J Cancer","first-page":"78","article-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","volume":"50","author":"Bianchini D","year":"2014","unstructured":"Bianchini D, Lorente D, Rodriguez-Vida A,  Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014;50:78\u201384."},{"key":"B173","series-title":"Eur Urol","first-page":"10","article-title":"Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302","volume":"72","author":"Smith MR","year":"2017","unstructured":"Smith MR, Saad F, Rathkopf DE,  Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol 2017;72:10\u201313."},{"key":"B174","series-title":"Lancet Oncol","first-page":"1730","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf DJ","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S,  Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019;20:1730\u20131739."},{"key":"B175","series-title":"Lancet","first-page":"797","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman MS","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S,  [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021;397:797\u2013804."},{"key":"B176","series-title":"JAMA Netw Open","first-page":"e2110950","article-title":"Olaparib vs cabazitaxel in metastatic castration-resistant prostate cancer","volume":"4","author":"Wallis CJD","year":"2021","unstructured":"Wallis CJD, Klaassen Z, Jackson WC,  Olaparib vs cabazitaxel in metastatic castration-resistant prostate cancer. JAMA Netw Open 2021;4:e2110950."},{"key":"B177","series-title":"Ann Oncol","first-page":"1613","article-title":"Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer","volume":"15","author":"Abratt RP","year":"2004","unstructured":"Abratt RP, Brune D, Dimopoulos MA,  Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004;15:1613\u20131621."},{"key":"B178","series-title":"Clin Cancer Res","first-page":"3621","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio AM","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG,  Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:3621\u20133630."},{"key":"B179","series-title":"Am J Clin Oncol","first-page":"535","article-title":"High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer","volume":"27","author":"Beer TM","year":"2004","unstructured":"Beer TM, Garzotto M, Katovic NM. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol 2004;27:535\u2013541."},{"key":"B180","series-title":"Urology","first-page":"354","article-title":"Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer","volume":"67","author":"Cabrespine A","year":"2006","unstructured":"Cabrespine A, Guy L, Khenifar E,  Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology 2006;67:354\u2013359."},{"key":"B181","series-title":"Clin Prostate Cancer","first-page":"37","article-title":"Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer","volume":"1","author":"Harris KA","year":"2002","unstructured":"Harris KA, Harney E, Small EJ. Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer. Clin Prostate Cancer 2002;1:37\u201341."},{"key":"B182","series-title":"Anticancer Res","first-page":"4317","article-title":"Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure","volume":"30","author":"Ladoire S","year":"2010","unstructured":"Ladoire S, Eymard JC, Zanetta S,  Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res 2010;30:4317\u20134323."},{"key":"B183","series-title":"Br J Cancer","first-page":"2472","article-title":"Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed","volume":"110","author":"Lee JL","year":"2014","unstructured":"Lee JL, Ahn JH, Choi MK,  Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. Br J Cancer 2014;110:2472\u20132478."},{"key":"B184","series-title":"Ann Oncol","first-page":"703","article-title":"Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features","volume":"20","author":"Loriot Y","year":"2009","unstructured":"Loriot Y, Massard C, Gross-Goupil M,  Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20:703\u2013708."},{"key":"B185","series-title":"BJU Int","first-page":"308","article-title":"Response to docetaxel\/ carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer","volume":"101","author":"Nakabayashi M","year":"2008","unstructured":"Nakabayashi M, Sartor O, Jacobus S,  Response to docetaxel\/ carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 2008;101:308\u2013312."},{"key":"B186","series-title":"J Clin Oncol","first-page":"477","article-title":"Weekly doxorubicin in endocrine- refractory carcinoma of the prostate","volume":"1","author":"Torti FM","year":"1983","unstructured":"Torti FM, Aston D, Lum BL,  Weekly doxorubicin in endocrine- refractory carcinoma of the prostate. J Clin Oncol 1983;1:477\u2013482."},{"key":"B187","series-title":"Br J Cancer","first-page":"620","article-title":"A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred diethylstilbestrol","volume":"104","author":"Shamash J","year":"2011","unstructured":"Shamash J, Powles T, Sarker SJ,  A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred diethylstilbestrol. Br J Cancer 2011;104:620\u2013628."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/11\/article-p469.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/11\/article-p469.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/11\/article-p469.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:56:40Z","timestamp":1762783000000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/11\/article-p469.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":187,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.0052","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}